title: CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models.
abstract: Microglia, the primary immune effector cells in the brain, continually monitor the tissue parenchyma for pathological alterations and become activated in Alzheimer's disease. Loss of signaling between neurons and microglia via deletion of the microglial receptor, CX3CR1, worsens phenotypes in various models of neurodegenerative diseases. In contrast, CX3CR1 deficiency ameliorates pathology in murine stroke models. To examine the role of CX3CR1 in Alzheimer's disease-related β-amyloid pathology, we generated APPPS1 and R1.40 transgenic mouse models of Alzheimer's disease deficient for CX3CR1. Surprisingly, CX3CR1 deficiency resulted in a gene dose-dependent reduction in β-amyloid deposition in both the APPPS1 and R1.40 mouse models of AD. Immunohistochemical analysis revealed reduced staining for CD68, a marker of microglial activation. Furthermore, quantitative immunohistochemical analysis revealed reduced numbers of microglia surrounding β-amyloid deposits in the CX3CR1-deficient APPPS1 animals. The reduced β-amyloid pathology correlated with reduced levels of TNFα and CCL2 mRNAs, but elevated IL1β mRNA levels, suggesting an altered neuroinflammatory milieu. Finally, to account for these seemingly disparate results, both in vitro and in vivo studies provided evidence that CX3CL1/CX3CR1 signaling alters the phagocytic capacity of microglia, including the uptake of Aβ fibrils. Taken together, these results demonstrate that loss of neuron-microglial fractalkine signaling leads to reduced β-amyloid deposition in mouse models of AD that is potentially mediated by altered activation and phagocytic capability of CX3CR1-deficient microglia.
authors.affiliation: Lerner Research Institute, The Cleveland Clinic, Department of Neurosciences, Case Western Reserve University School of Medicine, 9500 Euclid Avenue, NC30, Cleveland, OH 44195-0001, USA.
authors.forename: Sungho
authors.initials: S
authors.lastname: Lee
authors.forename: Nicholas H
authors.initials: NH
authors.lastname: Varvel
authors.forename: Megan E
authors.initials: ME
authors.lastname: Konerth
authors.forename: Guixiang
authors.initials: G
authors.lastname: Xu
authors.forename: Astrid E
authors.initials: AE
authors.lastname: Cardona
authors.forename: Richard M
authors.initials: RM
authors.lastname: Ransohoff
authors.forename: Bruce T
authors.initials: BT
authors.lastname: Lamb
mesh_terms: D000544:Alzheimer Disease / Q000378:metabolism* / Q000473:pathology*; D016564:Amyloid beta-Protein Precursor / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D000073883:CX3C Chemokine Receptor 1; D002465:Cell Movement; D049109:Cell Proliferation; D054428:Chemokine CX3CL1 / Q000235:genetics / Q000378:metabolism; D004195:Disease Models, Animal; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D017628:Microglia / Q000378:metabolism*; D009474:Neurons / Q000378:metabolism; D010587:Phagocytosis; D019707:Receptors, Chemokine / Q000172:deficiency* / Q000235:genetics
chemical_list: D016564:Amyloid beta-Protein Precursor; D000073883:CX3C Chemokine Receptor 1; D054428:Chemokine CX3CL1; C471885:Cx3cr1 protein, mouse; D019707:Receptors, Chemokine